These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12201927)

  • 1. Severe symptomatic osteoporosis in patients on androgen deprivation therapy for prostatic carcinoma.
    Paterson CR; Mole PA
    Scand J Urol Nephrol; 2002; 36(4):314-6. PubMed ID: 12201927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T
    Cancer; 2005 Jan; 103(2):237-41. PubMed ID: 15597384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer.
    Weston R; Hussain A; George E; Parr NJ
    BJU Int; 2005 Apr; 95(6):776-9. PubMed ID: 15794781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of osteoporosis in men treated for prostate cancer.
    Oefelein MG; Resnick MI
    Urol Clin North Am; 2004 May; 31(2):313-9. PubMed ID: 15123410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Percutaneous vertebroplasty in the treatment of osteoporotic vertebral compression fractures: first short term results].
    Voormolen MH; Lohle PN; Fransen H; Juttmann JR; de Waal Malefijt J; Lampmann LE
    Ned Tijdschr Geneeskd; 2003 Aug; 147(32):1549-53. PubMed ID: 12942845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM; Pasini J; Mareković Z
    Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of new osteoporotic vertebral compression fractures in the year after percutaneous vertebroplasty.
    Voormolen MH; Lohle PN; Juttmann JR; van der Graaf Y; Fransen H; Lampmann LE
    J Vasc Interv Radiol; 2006 Jan; 17(1):71-6. PubMed ID: 16415135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systemic mastocytosis--rare cause of pathologic vertebral fracture].
    Stamm AC; Burbelko M; Rominger M
    Rofo; 2008 Jan; 180(1):57-9. PubMed ID: 17968773
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    Diamond TH; Bucci J; Kersley JH; Aslan P; Lynch WB; Bryant C
    J Urol; 2004 Aug; 172(2):529-32. PubMed ID: 15247721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    Ockrim JL; Lalani EN; Abel PD
    J Urol; 2005 May; 173(5):1829; author reply 1829-30. PubMed ID: 15821605
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    Pitts WR
    J Urol; 2005 May; 173(5):1829; author reply 1829-30. PubMed ID: 15821604
    [No Abstract]   [Full Text] [Related]  

  • 19. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.